Overview

Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the effectiveness and tolerability of controlled-release paroxetine (Paxil-CR) compared to placebo (an inactive substance) for individuals who continue to have symptoms of post traumatic stress disorder (PTSD) despite receiving prolonged exposure therapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Treatments:

Paroxetine